AstraZeneca PLC — Company profile
Healthcare · Drug Manufacturers - General · United Kingdom
Last price 174.4 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 270.72B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.
Details
| Name | AstraZeneca PLC |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 95100 |
| Founded | 1992 |
| Ipo Date | 1993-05-12 |
| Ceo | Pascal Claude Soriot |
| Country | United Kingdom |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | GB0009895292 |
| Cusip | G0593M107 |
| Cik | 0000901832 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Pascal Claude Roland Soriot D.V.M., M.B.A. | Chief Executive Officer and Executive Director |
| Dr. Aradhana Sarin M.D. | Chief Financial Officer and Executive Director |
| Pam P. Cheng | Executive Vice President of Global opt. and IT, Chief Sust. Officer and Member of External Sust.Adv. Board |
| Joris Silon | Head of Investor Relations |
| Jeffrey Pott J.D. | CHRO, Chief Compliance Officer, General Counsel and Member of External Sustainability Advisory Board |
| Dr. Ruud Dobber Ph.D. | Executive Vice-President of BioPharmaceuticals Business Unit |
| Dr. Susan Mary Galbraith M.D., Ph.D. | Executive Vice President of Oncology Research & Development |
| Iskra Reic | Executive Vice President of International |
| David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit |
| Ruth March FMEDSCI, O.B.E., Ph.D. | Senior Vice President of Precision Medicine - Research & Development Oncology |
Contact
| Address | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, United Kingdom |
| Phone | 44 20 3749 5000 |
| Website | https://www.astrazeneca.com |